BNAC is a dedicated research center for qualitative and quantitative analysis of MRI for clinical research including conduct of Preclinical and Clinical Phase I, II, III, and IV trials and investigator-led research studies on multiple sclerosis (MS) and other neurodegenerative diseases. BNAC ensures fast contracting, ethical committee approval and start-up processes, and is structured to manage multiple projects with tens of thousands of scans. BNAC brings to every clinical trial a high degree of professionalism and integrity that stipulates unequivocal respect for deadlines and commitments. BNAC has been involved in 55 clinical trials in multiple sclerosis, Parkinson’s disease and stroke with >90% of the clinical trials being conducted in MS alone.

BNAC has calculated qualitative and quantitative imaging metrics on over 11,000 subjects and 40,000 MRI scans deriving from various clinical trials. BNAC served as a centralized imaging center in 4 phase III regulatory clinical trials, of which 3 have been already approved by Food and Drug Administration (FDA) and the 4th study is currently under way. A summary of BNAC’s clinical trial activities is provided below.